Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor.
- The company can now initiate clinical trial agreement negotiations and institutional review board submissions.
- The randomized, controlled clinical trial was designed to support U.S. marketing submission for CytoSorb, to remove AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) during the cardiothoracic surgery to reduce perioperative bleeding complications.
- Ticagrelor is one of the most commonly used blood thinners to reduce the risk of cardiac death, heart attacks, and strokes in patients with the acute coronary syndrome.
- It is also used to reduce the rate of stent thrombosis in patients who have been stented.
- However, when patients on ticagrelor require emergent cardiac surgery, the risk of severe bleeding and complications is very high.
- Last year in January, CytoSorb scored approval in the E.U. to remove ticagrelor during surgery requiring cardiopulmonary bypass.
- In April 2020, CytoSorb received FDA Breakthrough Designation to remove ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
- Price Action: CTSO shares are down 2.2% at $8.8 in market trading hours on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!